Concretely: a quantified content assay · fibrillation · dulaglutide.
These are treated as interchangeable and I do not think they are.
If both are acceptable I would like to know that, so I can stop thinking about it.
What is the actual trade-off, and does it matter at the scale I am working at?
The honest answer is that mapping is the only routine way to localise a substitution short of full sequencing.
The result is compared against the theoretical digest of the claimed sequence. A fragment at an unexpected mass localises a problem to a few residues; a missing expected fragment does the same from the other direction.
Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.
Trypsin cleaving C-terminal to lysine and arginine, except before proline, is the standard specificity and is what makes a theoretical digest predictable.
Nothing here is medical advice, and research-use compounds are not approved for human use.
A missing expected fragment is as informative as an unexpected one.
edited 9 Aug 2025 by n_takahashi — fixed an arithmetic slip in the third paragraph
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemPost-translational and chemical modifications show up as a mass shift on a specific fragment, which is exactly the information intact mass throws away.
Disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.
Missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.
Peptide mapping is a compendial identity method for peptide and protein products and is specified in the relevant pharmacopoeial general chapters.
Coverage below about ninety-five per cent leaves real gaps, and the reported coverage figure should always accompany the conclusion.
Ask for the coverage figure with any map. Without it the result is not interpretable.
edited 9 Aug 2025 by mz_4113 — added the placebo-arm figures
Answering this needs to know whether a mass-neutral substitution is plausible for the sequence, since that is the case mapping is for.
A D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.
Specifically, cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.
Nobody at this tier supplies mapping as standard; it is something you commission.
Commission it on a first lot from a new supplier, not on every lot.
This is the most informative single test available for a peptide identity question and it is rarely on a research-grade certificate.
For a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.
Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.
Non-reduced mapping is how you confirm disulfide pairings.
Coverage is the metric that decides whether a map means anything: an eighty per cent map has left a fifth of the sequence unexamined.
The workflow: reduce and alkylate any disulfides, digest with a specific protease — trypsin cleaving after lysine and arginine is the usual choice — separate the fragments by reverse-phase chromatography, and identify each by mass.
The caveat is that a map confirms sequence and says nothing about content, sterility or endotoxin.
Mapping is for mass-neutral problems. That is when it earns its cost.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.